Medication price comparisons remain opaque because multiple price definitions exist and patients typically learn ...

Teledentistry has become an important tool for helping patients access dental expertise when and where they need it. It can ...

Just two therapies are available to treat MASH. The first was Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), which was ...

Moving the 340B program from upfront discounts to a rebate model would add work for health systems but likely wouldn't change the picture for employers and other plan sponsors, ac ...

Meta-analysis of 13 RCTs (2002–2024; eight countries) found VR reduced pain (SMD −0.76) and anxiety (SMD −1.53), largely ...

Employers that decide to stop covering GLP-1s for weight loss are increasingly pairing that decision with support for the ...

HRI Dental & Vision, a dental benefits organization providing dental plans, provider networks and dental review services to h ...

In stage II–IIIA disease, adjuvant osimertinib reduced mortality risk by 47%, with 74% alive at eight years versus 58% with ...

Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx. Employers and other plan sponsors have few good options for ...

GLP-1 therapies continue to materially influence drug spend, with 2025 overall trend at 8.4% versus 7.9% excluding GLP-1s, ...

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point ...

Poh says treatment of follicular lymphoma is entering an exciting era in follicular lymphoma with multiple treatment options ...